Last reviewed · How we verify

Azathioprine OR Mesalazine

Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Phase 3 active Small molecule

Azathioprine OR Mesalazine is a Immunosuppressant and anti-inflammatory combination Small molecule drug developed by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. It is currently in Phase 3 development for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Induction and maintenance of remission in IBD.

This is a combination therapy study comparing azathioprine (an immunosuppressant) and mesalazine (an anti-inflammatory) for inflammatory bowel disease.

This is a combination therapy study comparing azathioprine (an immunosuppressant) and mesalazine (an anti-inflammatory) for inflammatory bowel disease. Used for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Induction and maintenance of remission in IBD.

At a glance

Generic nameAzathioprine OR Mesalazine
SponsorGroupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Drug classImmunosuppressant and anti-inflammatory combination
TargetPurine metabolism (azathioprine); NF-κB pathway (mesalazine)
ModalitySmall molecule
Therapeutic areaGastroenterology / Immunology
PhasePhase 3

Mechanism of action

Azathioprine is a purine analog that suppresses T-cell mediated immunity by inhibiting DNA synthesis in lymphocytes. Mesalazine (5-aminosalicylic acid) acts locally in the colon to reduce inflammation through inhibition of NF-κB and production of anti-inflammatory mediators. Together they target both immune suppression and local mucosal inflammation in IBD.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Azathioprine OR Mesalazine

What is Azathioprine OR Mesalazine?

Azathioprine OR Mesalazine is a Immunosuppressant and anti-inflammatory combination drug developed by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives, indicated for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Induction and maintenance of remission in IBD.

How does Azathioprine OR Mesalazine work?

This is a combination therapy study comparing azathioprine (an immunosuppressant) and mesalazine (an anti-inflammatory) for inflammatory bowel disease.

What is Azathioprine OR Mesalazine used for?

Azathioprine OR Mesalazine is indicated for Inflammatory bowel disease (Crohn's disease or ulcerative colitis), Induction and maintenance of remission in IBD.

Who makes Azathioprine OR Mesalazine?

Azathioprine OR Mesalazine is developed by Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (see full Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives pipeline at /company/groupe-d-etude-therapeutique-des-affections-inflammatoires-digestives).

What drug class is Azathioprine OR Mesalazine in?

Azathioprine OR Mesalazine belongs to the Immunosuppressant and anti-inflammatory combination class. See all Immunosuppressant and anti-inflammatory combination drugs at /class/immunosuppressant-and-anti-inflammatory-combination.

What development phase is Azathioprine OR Mesalazine in?

Azathioprine OR Mesalazine is in Phase 3.

What are the side effects of Azathioprine OR Mesalazine?

Common side effects of Azathioprine OR Mesalazine include Nausea and gastrointestinal upset, Bone marrow suppression, Hepatotoxicity, Pancreatitis, Headache, Rash.

What does Azathioprine OR Mesalazine target?

Azathioprine OR Mesalazine targets Purine metabolism (azathioprine); NF-κB pathway (mesalazine) and is a Immunosuppressant and anti-inflammatory combination.

Related